Dr. Michael Henderson, MD, is the CEO at Apogee Therapeutics. He is a proven biotechnology industry leader with expertise in business leadership, drug development and commercial strategy. Throughout his career, Henderson has spearheaded the creation of more than 20 companies, launched 40 drug development programs and led two teams to FDA approvals.
Under his leadership, Apogee has grown substantially in the past three years, including raising nearly $1 billion in financing as well as initiating Phase I and II clinical trials across five different clinical programs. Phase III trial planning is in progress for lead program APG777, a potential best-in-class treatment, next year.
Before joining Apogee, Henderson served as chief business officer of BridgeBio Pharma, a commercial-stage biopharmaceutical company. He was responsible for furthering its overarching strategy, identifying and investing in new technologies and running business development and operations. He also served in leadership positions for several prominent subsidiary companies of BridgeBio.
Prior to BridgeBio, Henderson worked at McKinsey & Company, before which he co-founded PellePharm. He currently serves on the board of Spyre Therapeutics. Henderson received his Bachelor of Arts from Harvard University and has a Doctor of Medicine from Stanford University.